Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Adage Capital Management Reiterates Stake in CARDIOME PHARMA CORP (CRME)

In its latest filing, Adage Capital Management, managed by Phill Gross and Robert Atchinson, has reported ownership of 1.33 million shares of CARDIOME PHARMA CORP (NASDAQ:CRME). The stake amasses 8.9% of the company’s common shares, and is unchanged from the end of the third quarter of 2013.

Phill Gross Adage Capital Management

CARDIOME PHARMA CORP (NASDAQ:CRME) is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.

Jim Simons’s Renaissance Technologies owned 210,113 shares of CARDIOME PHARMA CORP (NASDAQ:CRME) at the end of third quarter of 2013. Ken Griffin’s Citadel Investment Group held 10,782 shares of the company by the end of third quarter.

In late November 2013, Fortress Investment Group, managed by Michael Novogratz, reported adding CARDIOME PHARMA CORP (NASDAQ:CRME) to its equity portfolio, in a new filing with the Securities and Exchange Commission. Fortress disclosed a passive stake, which amasses 2.5 million shares, with an aggregate value of $15.4 million at the current share price of the company.

The largest stake in Adage Capital equity portfolio is represented by Apple Inc. (NASDAQ:AAPL), in which Adage Capital disclosed 1.38 million shares worth about $657.41 million.

Adage Capital was founded by Phil Gross and Robert Atchinson in 2001. Gross was initially a healthcare and retail analyst at the Harvard Management Company (HMC). Later, he became a partner at the company, where he spent 18 years.

In December, Adage Capital reported raising its exposure to Heartware International Inc. (NASDAQ:HTWR) to 836,190 shares, from 688,952 shares held at the end of September, as revealed in the fund’s latest 13G. Adage Capital Management disclosed ownership of 5.07% of the company’s common stock.

Disclosure: none

Recommended Reading:

Deerfield Management Further Raises Its Position in Auspex Pharmaceuticals Inc (ASPX)

Iroquois Capital Edges up Stake in National Holdings Corporation (NHLD)

Cannell Capital Boosts its Stake in ZipRealty, Inc. (ZIPR)

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...